当前位置：药药网 / 药品研发 / 美国药品上市后承诺数据库
FluBlok, Influenza Vaccine
申请企业
Protein Sciences Corporation
药品名称
FluBlok, Influenza Vaccine
承诺描述
Deferred pediatric safety, immunogenicity and efficacy study (PSC17) in children 3 years through 17 years of age for active immunization for the prevention of disease caused by influenza virus subtypes A and types B contained in Flublok Quadrivalent.
承诺状态描述
Per FDA letter dated July 15, 2020, this PMR has been Released.